Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Raffoul, Julian J ^a   Wang, Yu ^a   Kucuk, Omer ^a,b   Forman, Jeffrey D ^a,b   Sarkar, Fazlul H ^a   Hillman, Gilda G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; CYCLIN B; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; GENISTEIN; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS;

EID: 33646727546     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-107     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer Statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Zietman AL, Shipley WU, Willett CG: Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 1993, 71(3 Suppl):959-969.
3. Forman JD: Neutron radiation for prostate cancer. Prostate J 1999, 1:8-14.
4. Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF, Rivlin R, Simopoulos A, Wargovich MJ, Weisburger EK, Zeisel SH: The role of dietary supplements during cancer therapy. J Nutr 2003, 133:3794S-3799S.
5. Norman HA, Go VL, Butrum RR: Review of the international research conference on food, nutrition, and cancer, 2004. J Nutr 2004, 134:3391S-3393S.
6. Knight DC, Eden JA: A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996, 87:897-904.
7. Mills R, Beeson W, Phillips R, Fraser G: Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989, 64:598-604.
8. Giovannucci E: Epidemiologic characteristics of prostate cancer. Cancer 1995, 75:1766-1777.
9. Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT: Soybean phytoestrogen intake and cancer risk. J Nutr 1995, 125:757S-770S.
10. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375:577-581.
11. Tatsuta M, Iishi H, Baba M, Yano H, Uehara H, Nakaizumi A: Attenuation by genistein of sodium chloride enhances gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer 1999, 80:396-399.
12. Okura A: Effect of genistein on topoisomerase activity and on the cell growth of val[12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 1988, 157:183-189.
13. Adlercreutz H: Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Investig 1990, 201 (Suppl):3-23.
14. Huang J, Nasr M, Kim Y, Matthews HR: Genistein inhibits protein histidine kinase. J Biol Chem 1992, 267:15511-15515.
15. Sarkar FH, Li Y: The role of isoflavones in cancer chemoprevention. Front Biosci 2004, 9:2714-24.
16. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I: Growth inhibitory effect of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 1994, 30:1675-1682.
17. Constantinou A, Huberman E: Genistein as an inducer of tumor cell differentiation: possible mechanisms of action. Proc Soc Exp Biol Med 1995, 208:109-115.
18. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997, 51:193-200.
19. Spinnozi F, Pagliacci M, Migliorati G, Moraca R, Grignani F, Ricardi C, Nicoletti I: The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T leukemia cells. Leuk Res 1994, 18:431-439.
20. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999, 18:3166-3172.
21. Li Y, Bhuiyan M, Sarkar FH: Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 1999, 15:525-533.
22. Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH: Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer 1999, 34:12-19.
23. WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998, 32:123-131.
24. Hillman GG, Forman JD, Kucuk O, Yudelev M, Maughan RL, Rubio J, Layer A, Tekyi-Mensah S, Abrams J, Sarkar FH: Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res 2001, 7:382-390.
25. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, Sarkar FH: Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004, 3:1271-1279.
26. Hillman GG: Experimental animal models for renal cell carcinoma. In Tumor Models in Cancer Research Edited by: Teicher BA. Totowa, NJ, Humana Press; 2002:493-505.
27. Hashimura T, Tubbs RR, Connelly R, Caulfield MJ, Trindade CS, McMahon JT, Galetti TP, Edinger M, Sandberg AA, Cin PD, Sait SJ, Pontes JE: Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma. Cancer Res 1989, 49:7064-71.
28. Raffoul JJ, Cabelof DC, Nakamura J, Meira LB, Friedberg EC, Heydari AR: Apurinic/apyrimidinic endonuclease (APE/REF-1) haploinsufficient mice display tissue-specific differences in DNA polymerase beta-dependent base excision repair. J Biol Chem 2004, 279:18425-33.
29. Davis JN, Kucuk O, Sarkar FH: Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999, 35:167-174.
30. Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:928-42.
31. Geldof AA, Plaizier MA, Duivenvoorden I, Ringelberg M, Versteegh RT, Newling DW, Teule GJ: Cell cycle perturbations and radio-sensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol 2003, 129:175-82.
32. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-4.
33. Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994, 9:2261-8.
34. El-Deiry WS: Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 2001, 3:E71-3.
35. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991, 51:4716-20.
36. Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000, 92:376-387.
37. Yan S-X, Ejima Y, Sasaki R, Zheng S-S, Demizu Y, Soejima T, Sugimura K: Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells. Asian J Androl 2004, 6:285-290.
38. Yashar CM, Spanos WJ, Taylor DD, Gercel-Taylor C: Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol Oncol 2005, 99:199-205.
39. Lin A, Karin M: NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003, 13:107-114.
40. Yamamoto Y, Gaynor RB: Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001, 1:287-296.
41. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
42. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L: Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004, 10:5501-5507.
43. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S: Nuclear factor-kappaB/p65 (Rel A) is constitutively activated In human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004, 6:390-400.
44. Li Y, Ellis KL, Ali S, El-Rayes B, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH: Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κB in BxPC-3 pancreatic cancer cell line. Pancreas 2004, 28:e90-e95.
45. Ozeki M, Tamae D, Hou DX, Wang T, Lebon T, Spitz DR, Li JJ: Response of cyclin B1 to ionizing radiation: regulation by NF-kappaB and mitochondrial antioxidant enzyme MnSOD. Anticancer Res 2004, 24:2657-63.
46. 2-M arrest by nuclear factor-κB-dependent p21 waf1/cip1 induction. Mol Cancer Res 2005, 3:345-53.
47. Li Y, Ahmad F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005, 65:6934-42.
48. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005, 65:9064-9072.
49. Davis DA, Sarkar SH, Hussain M, Li Y, Sarkar FH: Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006, 6:22.
50. Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH: Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006, 106:1260-1268.